Immune therapies have transformed the landscape of oncology. Immune checkpoint inhibitors are group of medications, which activate T-Cells to fight against cancer cells. Acute tubulointrestitial nephritis is the most common form of kidney immune-related adverse event. With more use of ICPIs, renal immune related side effects are being recognized more. Here we present a case of renal tubular acidosis with acute kidney injury in a patient with squamous cell carcinoma of the skull who was on Cemiplimab.
SeethapathyHZhaoSChuteDF, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol2019; 14: 1692–1700.
2.
CortazarFBMarroneKATroxellML, et al. Clinicopatho-logical features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int2016; 90: 638–647.
3.
CortazarFBKibbelaarZAGlezermanIG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol2020; 31: 435–446.
4.
OleasDBoluferMAgrazI, et al. Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Clin Kidney J. 14(5): 1364-1370.
5.
CharmetantXTeumaCLakeJ, et al. A new expression of immune checkpoint inhibitors’ renal toxicity: when distal tubular acidosis precedes creatinine elevation. Clin Kidney J2020; 13: 42–45.
6.
GallanAJAlexanderEReidP, et al. Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors. Am J Kidney Dis2019; 74(6): 853–856.
7.
MamloukOSelamatUMachadoS, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer2019; 7(1): 2.
8.
El BitarSWeerasingheCEl-CharabatyE, et al. Renal tubular acidosis an adverse effect of PD-1 inhibitor immunotherapy. Case Rep Oncol Med2018; 2018: 8408015.
9.
HerrmannSMAlexanderMPRomeroMF, et al. Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 Inhibitor—a report of 3 cases. Kidney Med2020; 2(5): 657–662.
10.
AtiqSOGokhaleTAtiqZ, et al. A case of pembrolizumab induced distal renal tubular acidosis. J Onco-Nephrol. 5(1): 23-26.
11.
PerazellaMAShiraliAC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?Kidney Int2020; 97(1): 62–74.
SeethapathyHZhaoSStrohbehnIA, et al. Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors. Kidney Int Rep2020; 5(10): 1700–1705.
14.
PhillaiRNBeheraMOwonikokoTK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non–small cell lung cancer: a systematic analysis of the literature. Cancer2018; 124: 271–277.
15.
BobartSAOwoyemiIGrandeJ, et al. Immune check point inhibitor–associated endothelialitis. Kidney Int Rep2020; 5: 1371–1374.
16.
QinSXuLYiM, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer2019;18: 155.
